Testing effectiveness (Phase 2)WithdrawnNCT03760445What this trial is testingHDM201 Added to CT in R/R or Newly Diagnosed AMLWho this might be right forLeukemia, Myeloid, Acute Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT03379727What this trial is testingStudy to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.Who this might be right forAcute Myeloid Leukemia Novartis Pharmaceuticals 301
Large-scale testing (Phase 3)Study completedNCT02421939What this trial is testingASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationWho this might be right forLeukemia, Acute Myeloid (AML) Astellas Pharma Global Development, Inc. 371
Testing effectiveness (Phase 2)WithdrawnNCT03324243What this trial is testingCrenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaWho this might be right forRelapsed/Refractory FLT3-mutated AML Arog Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04209725What this trial is testingCPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaWho this might be right forLeukemia, Myeloid, Acute SCRI Development Innovations, LLC 1
Testing effectiveness (Phase 2)UnknownNCT03135054What this trial is testingCombination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITDWho this might be right forAMLFLT3-ITD Mutation The University of Hong Kong 40
Testing effectiveness (Phase 2)Study completedNCT00045942What this trial is testingPKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)Who this might be right forAcute Myeloid LeukemiaMyelodysplastic Syndromes Novartis Pharmaceuticals 144
Testing effectiveness (Phase 2)Study completedNCT03280030What this trial is testingMidostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AMLWho this might be right forAcute Myeloid Leukemia Novartis Pharmaceuticals 67
Testing effectiveness (Phase 2)Study completedNCT00783653What this trial is testingClinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 YearsWho this might be right forAcute Myeloid Leukemia Universitätsklinikum Hamburg-Eppendorf 22
Early research (Phase 1)Looking for participantsNCT06313437What this trial is testingRevumenib in Combination With 7+3 + Midostaurin in AMLWho this might be right forAcute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more Richard Stone, MD 22
Very early researchStudy completedNCT04518345What this trial is testingTP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia Uma Borate 3
Not applicableUnknownNCT05383014What this trial is testingFLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.Who this might be right forAcute Myeloid Leukemia Assiut University 82
Not applicableUnknownNCT03547258What this trial is testingItalian Non-Interventional Study of FLT3 Mutated AML PatientsWho this might be right forAMLFLT3-ITD MutationFLT3-TKD Mutation Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 800
Testing effectiveness (Phase 2)Study completedNCT01883362What this trial is testingStandard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLWho this might be right forAcute Myeloid Leukemia Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT02984995What this trial is testingPhase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) MutationWho this might be right forLeukemia, Myeloid, Acute Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)Looking for participantsNCT06022003What this trial is testingStudy Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaWho this might be right forAML, AdultRefractory AMLRelapsed Adult AML+2 more French Innovative Leukemia Organisation 33
Early research (Phase 1)WithdrawnNCT05330377What this trial is testingGM-CLAG in Relapsed/Refractory FLT3-mutated AMLWho this might be right forAcute Myeloid Leukemia Ayman H Qasrawi
Testing effectiveness (Phase 2)Active Not RecruitingNCT05520567What this trial is testingGilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia Astellas Pharma Global Development, Inc. 70
Testing effectiveness (Phase 2)Study completedNCT01831726What this trial is testingDovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibWho this might be right forTumor Pathway Activations Inhibited by Dovitinib Novartis Pharmaceuticals 80
Large-scale testing (Phase 3)Not Yet RecruitingNCT07407140What this trial is testingVAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLWho this might be right forAML, Adult Institute of Hematology & Blood Diseases Hospital, China 300